银杏二萜内酯葡胺对急性脑梗死患者NSE、hs-CRP及生活质量的影响

doi:10.3969/j.issn.1004-583X.2021.09.004

摘要/Abstract

摘要：

目的研究银杏二萜内酯葡胺与巴曲酶联用对急性脑梗死(ACI)患者血清神经烯醇化酶(NSE)、超敏C反应蛋白(hs-CRP)及生活质量的影响。方法选取我院ACI患者108例,随机分为观察组与对照组,各54例。两组均行常规治疗,对照组在常规治疗基础上注射巴曲酶,观察组在对照组基础上加用银杏二萜内酯葡胺注射液,两组均持续治疗14 d。治疗14 d后观察两组临床疗效,于治疗前、治疗后1周、1个月、3个月评估两组Barthel指数,检测两组治疗前后血清中神经烯醇化酶(NSE)、超敏C反应蛋白(hs-CRP)水平,评估两组治疗第7 、15 、30 、60 d 改良Rankin量表(mRS)评分,并记录两组治疗期间不良反应发生情况。结果观察组总有效率为92.15%,显著高于对照组74.07%(P<0.05)。治疗后观察组 Barthel评分显著高于本组治疗前及对照组治疗后(P<0.05)。治疗后观察组NSE、hs-CRP水平显著低于治疗前及对照组(P<0.05)。观察组mRS评分显著低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论银杏二萜内酯葡胺联合巴曲酶治疗ACI有较好疗效,对患者生活活动功能、功能障碍、生活质量及预后情况均有明显改善效果,且安全性较高。

关键词: 脑梗死, 银杏二萜内酯葡胺, 巴曲酶

Abstract:

Objective To study the effect of ginkgolide meglumine combined with batroxobin on serum NSE, high-sensitivity C-reactive protein(hs-CRP) and quality-of-life in patients with acute cerebral infarction(ACI). Methods Totally 108 ACI inpatients were randomly divided into two groups. On the basis of routine treatment, 54 cases in control group were injected with batroxobin, and 54 cases in observation group with ginkgolide meglumine combined with batroxobin. After 14 days of treatment. The clinical efficacy, 1-week, 1-month, and 3-month Barthel index, serum of neuron-specific enolase(NSE) and hs-CRP in two groups were observed. The evaluations were performed in modified Rankin Scale(mRS) scores on the 7th, 15th, 30th and 60th day of treatment, and the incidence of adverse reactions during this period. Results The total effective rate was significantly higher in observation group than in control group (92.15% vs 74.07%, P<0.05). After treatment, Barthel score in observation group was significantly higher than that before treatment, and the score was higher than in control group(P<0.05). The NSE and hs-CRP were significantly lower in observation group than before treatment(P<0.05). mRS score was significantly lower in observation group as compared with control group(P<0.05). There was no significant difference in the incidence of adverse reactions between groups (P>0.05). Conclusion For ACI patients, Ginkgolide meglumine combined with batroxobin has good curative effect, which can significantly improve their activity function, dysfunction, quality-of-life, prognosis, and has high safety.

Key words: cerebral infarction, ginkgolide meglumine, batroxobin

中图分类号:

R743.33

黄旭冰, 林仰, 蔡雯靖. 银杏二萜内酯葡胺对急性脑梗死患者NSE、hs-CRP及生活质量的影响[J]. 临床荟萃, 2021, 36(9): 786-789.

Huang Xubing, Lin Yang, Cai Wenjing. Effect of ginkgolide meglumine in NSE, hs-CRP and quality-of-life of patients with acute cerebral infarction[J]. Clinical Focus, 2021, 36(9): 786-789.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.09.004

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I9/786

图/表 5

参考文献 18

[1]	Wang X, Sun Y, Dong S, et al. Butyphthalide in the treatment of massive cerebral infarction[J]. Pak J Med Sci, 2019, 35(1):220-225.
[2]	Sun Z, Xu Q, Gao G, et al. Clinical observation in edaravone treatment for acute cerebral infarction[J]. Niger J Clin Pract, 2019, 22(10):1324-1327. doi: 10.4103/njcp.njcp_367_18 pmid: 31607719
[3]	Politi M, Kastrup A, Marmagkiolis K, et al. Endovascular therapy for acute stroke[J]. Prog Cardiovasc Dis, 2017, 59(6):534-541. doi: S0033-0620(17)30049-X pmid: 28365297
[4]	Peisker T, Koznar B, Stetkarova I, et al. Acute stroke therapy: A review[J]. Trends Cardiovasc Med, 2017, 27(1):59-66. doi: 10.1016/j.tcm.2016.06.009 URL
[5]	李延珍, 李忠辉, 李良, 等. 银杏二萜内酯葡胺注射液对心肌缺血再灌注所致心律失常模型大鼠的影响[J]. 中国中医急症, 2018, 27(10):75-78.
[6]	周辉, 周少珑, 陈聪, 等. 巴曲酶注射液治疗急性缺血性脑卒中的临床研究[J]. 中国临床药理学杂志, 2019, 35(15):1549-1551, 1555.
[7]	中华医学会神经病学分会. 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4):246-257.
[8]	Kwah L K, Diong J. National institutes of health stroke scale (NIHSS)[J]. J Physiother, 2014, 60(1):61. doi: 10.1016/j.jphys.2013.12.012 URL
[9]	Kelly KM, Holt KT, Neshewat GM, et al. Community interventions to increase stroke preparedness and acute stroke treatment rates[J]. Curr Atheroscler Rep, 2017, 19(12):64. doi: 10.1007/s11883-017-0695-5 URL
[10]	马蓉, 徐弘扬, 杨锡彤, 等. 急性脑卒中治疗的研究进展[J]. 重庆医学, 2019, 48(6):1010-1013.
[11]	吴浩亮. 银杏二萜内酯对大鼠脑缺血再灌注后氧化应激和炎症反应抑制作用的研究[J]. 中西医结合心脑血管病杂志, 2019, 17(23):3717-3721.
[12]	曹骅, 张振昶. 银杏二萜内酯葡胺注射液治疗急性脑梗死疗效观察[J]. 西部中医药, 2019, 32(3):80-83.
[13]	Rabinstein AA. Treatment of acute ischemic stroke[J]. Continuum (Minneap Minn), 2017, 23(1):62-81.
[14]	Zhang W, Song JK, Yan R, et al. Diterpene ginkgolides protect against cerebral ischemia/reperfusion damage in rats by activating Nrf2 and CREB through PI3K/Akt signaling[J]. Acta Pharmacol Sin, 2018, 39(8):1259-1272. doi: 10.1038/aps.2017.149 pmid: 29542683
[15]	王燕, 赵铎, 王丹, 等. 银杏二萜内酯葡胺注射液联合奥扎格雷治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2019, 34(4):965-969.
[16]	刘满卓, 王慧, 赵素霞. 尤瑞克林联合阿托伐他汀治疗对急性脑梗死患者临床疗效, 氧化低密度脂蛋白及超敏C反应蛋白的影响[J]. 临床荟萃, 2020, 35(11):1001-1004.
[17]	李福军, 陈可, 马海玲, 等. 依达拉奉联合银杏二萜内酯对老年急性脑梗死患者的影响[J]. 实用心脑肺血管病杂志, 2019, 27(2):100-103.
[18]	冯红选, 桂千, 吴冠会, 等. 银杏二萜内酯葡胺注射液联合阿司匹林治疗大动脉粥样硬化型缺血性脑卒中的临床疗效[J]. 中国老年学杂志, 2020, 40(15):3158-3161.

组别	例数	性别[例(%)]		年龄 (岁)	病程 (h)	NIHSS (分)	体质量指数 (kg/m²)
组别	例数	男	女	年龄 (岁)	病程 (h)	NIHSS (分)	体质量指数 (kg/m²)
观察组	54	28(51.85)	26(48.15)	51.23±5.23	21.46±4.12	4.74±0.45	23.45±2.46
对照组	54	29(53.70)	25(46.30)	51.28±5.32	21.51±4.16	4.76±0.46	23.48±2.49
t/χ²值		0.037	0.037	0.049	0.063	0.228	0.063
P值		0.847	0.847	0.961	0.950	0.820	0.950

组别	例数	性别[例(%)]		年龄 (岁)	病程 (h)	NIHSS (分)	体质量指数 (kg/m²)
组别	例数	男	女	年龄 (岁)	病程 (h)	NIHSS (分)	体质量指数 (kg/m²)
观察组	54	28(51.85)	26(48.15)	51.23±5.23	21.46±4.12	4.74±0.45	23.45±2.46
对照组	54	29(53.70)	25(46.30)	51.28±5.32	21.51±4.16	4.76±0.46	23.48±2.49
t/χ²值		0.037	0.037	0.049	0.063	0.228	0.063
P值		0.847	0.847	0.961	0.950	0.820	0.950

组别	例数	痊愈	显效	有效	无效	总有效率
观察组	54	21(38.89)	20(37.04)	9(16.67)	4(7.41)	50(92.59)
对照组	54	16(29.63)	18(33.33)	6(11.11)	14(25.93)	40(74.07)
χ²值						6.667
P值						0.010

组别	例数	痊愈	显效	有效	无效	总有效率
观察组	54	21(38.89)	20(37.04)	9(16.67)	4(7.41)	50(92.59)
对照组	54	16(29.63)	18(33.33)	6(11.11)	14(25.93)	40(74.07)
χ²值						6.667
P值						0.010

组别	例数	Barthel评分
组别	例数	治疗前	治疗1周	治疗1月	治疗3月
观察组	54	43.23±5.12	47.96±5.49	52.88±6.03	57.26±6.42^#
对照组	54	42.26±5.16	44.03±5.03	46.93±5.85	50.31±6.43^#
组间		F=8.163 P=0.000
时点间		F=9.588 P=0.000
组间·时点间		F=13.849 P=0.000